Smith Group Asset Management’s Dr. Reddy's Laboratories RDY Stock Holding History

Smith Group Asset Management’s Portfolio RDY Stock Details RDY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-58,430	Closed	-$878K	–	188
2025 Q2	$878K	Buy	58,430 +15,430	+36%	+$220K	0.06%	97
2025 Q1	$567K	Sell	43,000 -400	-0.9%	-$5.52K	0.04%	125
2024 Q4	$685K	Buy	+43,400	New	+$652K	0.05%	110
2022 Q1	$629K	Sell	56,450 -500	-0.9%	-$5.67K	0.03%	107
2021 Q4	$745K	Sell	56,950 -1,500	-3%	-$18.9K	0.03%	114
2021 Q3	$761K	Buy	58,450 +6,950	+13%	+$92.6K	0.04%	103
2021 Q2	$757K	Buy	51,500 +3,200	+7%	+$44.8K	0.04%	98
2021 Q1	$593K	Buy	48,300 +3,200	+7%	+$41.1K	0.03%	121
2020 Q4	$643K	Sell	45,100 -4,000	-8%	-$53.9K	0.04%	113
2020 Q3	$683K	Sell	49,100 -11,650	-19%	-$139K	0.04%	115
2020 Q2	$644K	Sell	60,750 -10,650	-15%	-$108K	0.04%	120
2020 Q1	$576K	Buy	+71,400	New	+$595K	0.03%	115
2014 Q2	–	Sell	-28,975	Closed	-$254K	–	444
2014 Q1	$254K	Sell	28,975 -750	-3%	-$6.52K	0.01%	210
2013 Q4	$244K	Hold	29,725	–	–	0.01%	209
2013 Q3	$225K	Hold	29,725	–	–	0.01%	219
2013 Q2	$225K	Buy	+29,725	New	+$217K	0.01%	224

Other funds holding RDY

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

AIM

Aikya Investment Management London, United Kingdom $341M AUM 28.74% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Smith Group Asset Management's RDY Position: Q3 2025 in Review

Smith Group Asset Management sold out of Dr. Reddy's Laboratories (RDY) in Q3 2025, closing a stake of 58,430 shares — an estimated $878K sold.

Smith Group Asset Management first reported a position in RDY in Q2 2013 and held it in 16 quarters. The position peaked at $878K in Q2 2025. 228 funds tracked by Wall St. Rank hold RDY as of Q3 2025.

Smith Group Asset Management reported no remaining Dr. Reddy's Laboratories position as of Q3 2025 after selling out during the quarter.
Smith Group Asset Management sold 58,430 Dr. Reddy's Laboratories shares in Q3 2025, an estimated $878K.
Smith Group Asset Management first reported a position in Dr. Reddy's Laboratories in Q2 2013 and held it in 16 quarters.
Smith Group Asset Management's Dr. Reddy's Laboratories position peaked at $878K in Q2 2025.
228 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q3 2025.

Based on Smith Group Asset Management's 13F filing for Q3 2025, filed 13 Nov 2025.